Effects of Dexmedetomidine on Breast Cancer Cell Function in Vitro

RenJi Hospital24 enrolled

Overview

Dexmedetomidine is widely used as an anaesthetic for general anesthesia during surgery. Previous studies in cells and animals show that dexmedetomidine may promote cancer growth. Using serum from breast cancer surgery patients randomized to receive dexmedetomidine or saline during surgery, we investigated the effects of dexmedetomidine on proliferation, migration and metastasis in MCF-7 breast cancer cells in vitro.

Women diagnosed with breast cancer undergoing elective surgery under general anesthesia will be randomly allocated to dexmedetomidine group or control group. Patients from both groups will receive midazolam, propofol, fentanyl, remifentanil and CIS atracurium for total intravenous anesthesia. BIS value will be controlled between 40-60 during surgery. Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery. Patients of control group will receive same amount of normal saline. Serum will be collected from patients of both groups at before induction and 1h post-surgery. The MCF-7 breast cancer cell line will be treated with patient serum from both groups. The effects of dexmedetomidine on cellular proliferation, migration and metastasis will be measured.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Breast Cancer

Interventions

DexmedetomidineDRUG

Patients in the experimental group will receive Dexmedetomidine during surgery.

salineDRUG

Patients in the control group will receive saline but not Dexmedetomidine during surgery.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ASA grade I-III Age range of 18 to75 Patients diagnosed primary breast cancer(T2-3, N0-2, M0) Patients will have elective adenomammectomy Exclusion Criteria: * with history of breast operation Patients diagnosed carcinoma erysipelatodes Severe liver, renal, brain or lung disease with history of opioid addiction Patients diagnosed metastatic breast cancer

Locations (1)

Renji Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

cell proliferation

MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell proliferation will be measured

Time frame: 24 hour post-surgery

Secondary Outcomes

cell migration

MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell migration will be measured

Time frame: 24 hour post-surgery

cell metastasis

MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell metastasis will be measured

Time frame: 24 hour post-surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.